Evaluation of the use of botulinum toxin in children with achalasia

Melissa Hurwitz, Ron J. Bahar, Marvin E. Ament, Vasundhara Tolia, Jean Molleston, L. Julio Reinstein, J. Mark Walton, Nora Erhart, Dror Wasserman, Christopher Justinich, Jorge Vargas

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Background: Achalasia is rare in children. Recently, injection of botulinum toxin into the lower esophageal sphincter has been studied as an alternative to esophageal pneumatic dilatation or surgical myotomy as treatment for achalasia. In the current study, the effects of botulinum toxin were investigated in the largest known series of children with achalasia. Methods: Treatment for achalasia was assessed in 23 pediatric patients who received botulinum toxin from June 1995 through November 1998. Those who continued to receive botulinum toxin and did not subsequently undergo pneumatic dilatation or surgery were considered repeat responders. Results were compared with those of published studies evaluating the use of botulinum toxin in adults with achalasia. Results: Nineteen patients initially responded to botulinum toxin. Mean duration of effect was 4.2 months ± 4.0 (SD). At the end of the study period, three were repeat responders, three experienced dysphagia but did not receive pneumatic dilatation or surgery, three underwent pneumatic dilatation, eight under- went surgery, three underwent pneumatic dilatation with subsequent surgery, and three awaited surgery. Meta-analysis shows that, in the current study group, the data point expressing time of follow-up evaluation versus percentage of patients needing one injection session without additional procedures (botulinum toxin injection, pneumatic dilatation, or surgery) falls within the curve for those in studies on adult patients receiving botulinum toxin for achalasia. Conclusions: Botulinum toxin effectively initiates the resolution of symptoms associated with achalasia in children. However, one half of patients are expected to need an additional procedure approximately 7 months after one injection session. The authors recommend that botulinum toxin be used only for children with achalasia wh6 are poor candidates for either pneumatic dilatation or surgery. (C) 2000 Lippincott Williams and Wilkins, Inc.

Original languageEnglish (US)
Pages (from-to)509-514
Number of pages6
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume30
Issue number5
DOIs
StatePublished - May 2000
Externally publishedYes

Fingerprint

botulinum toxin
megaesophagus
Esophageal Achalasia
Botulinum Toxins
Dilatation
surgery
injection
Injections
esophageal sphincter
Lower Esophageal Sphincter
Deglutition Disorders
meta-analysis
signs and symptoms (animals and humans)
Meta-Analysis
Pediatrics

Keywords

  • Achalasia
  • Botulinum toxin
  • Esophageal pneumatic dilatation
  • Heller myotomy
  • Laparoscopy
  • Lower esophageal sphincter

ASJC Scopus subject areas

  • Gastroenterology
  • Histology
  • Medicine (miscellaneous)
  • Food Science
  • Pediatrics, Perinatology, and Child Health

Cite this

Evaluation of the use of botulinum toxin in children with achalasia. / Hurwitz, Melissa; Bahar, Ron J.; Ament, Marvin E.; Tolia, Vasundhara; Molleston, Jean; Reinstein, L. Julio; Walton, J. Mark; Erhart, Nora; Wasserman, Dror; Justinich, Christopher; Vargas, Jorge.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 30, No. 5, 05.2000, p. 509-514.

Research output: Contribution to journalArticle

Hurwitz, M, Bahar, RJ, Ament, ME, Tolia, V, Molleston, J, Reinstein, LJ, Walton, JM, Erhart, N, Wasserman, D, Justinich, C & Vargas, J 2000, 'Evaluation of the use of botulinum toxin in children with achalasia', Journal of Pediatric Gastroenterology and Nutrition, vol. 30, no. 5, pp. 509-514. https://doi.org/10.1097/00005176-200005000-00009
Hurwitz, Melissa ; Bahar, Ron J. ; Ament, Marvin E. ; Tolia, Vasundhara ; Molleston, Jean ; Reinstein, L. Julio ; Walton, J. Mark ; Erhart, Nora ; Wasserman, Dror ; Justinich, Christopher ; Vargas, Jorge. / Evaluation of the use of botulinum toxin in children with achalasia. In: Journal of Pediatric Gastroenterology and Nutrition. 2000 ; Vol. 30, No. 5. pp. 509-514.
@article{3652569bf16945fd9292ee85dab51972,
title = "Evaluation of the use of botulinum toxin in children with achalasia",
abstract = "Background: Achalasia is rare in children. Recently, injection of botulinum toxin into the lower esophageal sphincter has been studied as an alternative to esophageal pneumatic dilatation or surgical myotomy as treatment for achalasia. In the current study, the effects of botulinum toxin were investigated in the largest known series of children with achalasia. Methods: Treatment for achalasia was assessed in 23 pediatric patients who received botulinum toxin from June 1995 through November 1998. Those who continued to receive botulinum toxin and did not subsequently undergo pneumatic dilatation or surgery were considered repeat responders. Results were compared with those of published studies evaluating the use of botulinum toxin in adults with achalasia. Results: Nineteen patients initially responded to botulinum toxin. Mean duration of effect was 4.2 months ± 4.0 (SD). At the end of the study period, three were repeat responders, three experienced dysphagia but did not receive pneumatic dilatation or surgery, three underwent pneumatic dilatation, eight under- went surgery, three underwent pneumatic dilatation with subsequent surgery, and three awaited surgery. Meta-analysis shows that, in the current study group, the data point expressing time of follow-up evaluation versus percentage of patients needing one injection session without additional procedures (botulinum toxin injection, pneumatic dilatation, or surgery) falls within the curve for those in studies on adult patients receiving botulinum toxin for achalasia. Conclusions: Botulinum toxin effectively initiates the resolution of symptoms associated with achalasia in children. However, one half of patients are expected to need an additional procedure approximately 7 months after one injection session. The authors recommend that botulinum toxin be used only for children with achalasia wh6 are poor candidates for either pneumatic dilatation or surgery. (C) 2000 Lippincott Williams and Wilkins, Inc.",
keywords = "Achalasia, Botulinum toxin, Esophageal pneumatic dilatation, Heller myotomy, Laparoscopy, Lower esophageal sphincter",
author = "Melissa Hurwitz and Bahar, {Ron J.} and Ament, {Marvin E.} and Vasundhara Tolia and Jean Molleston and Reinstein, {L. Julio} and Walton, {J. Mark} and Nora Erhart and Dror Wasserman and Christopher Justinich and Jorge Vargas",
year = "2000",
month = "5",
doi = "10.1097/00005176-200005000-00009",
language = "English (US)",
volume = "30",
pages = "509--514",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Evaluation of the use of botulinum toxin in children with achalasia

AU - Hurwitz, Melissa

AU - Bahar, Ron J.

AU - Ament, Marvin E.

AU - Tolia, Vasundhara

AU - Molleston, Jean

AU - Reinstein, L. Julio

AU - Walton, J. Mark

AU - Erhart, Nora

AU - Wasserman, Dror

AU - Justinich, Christopher

AU - Vargas, Jorge

PY - 2000/5

Y1 - 2000/5

N2 - Background: Achalasia is rare in children. Recently, injection of botulinum toxin into the lower esophageal sphincter has been studied as an alternative to esophageal pneumatic dilatation or surgical myotomy as treatment for achalasia. In the current study, the effects of botulinum toxin were investigated in the largest known series of children with achalasia. Methods: Treatment for achalasia was assessed in 23 pediatric patients who received botulinum toxin from June 1995 through November 1998. Those who continued to receive botulinum toxin and did not subsequently undergo pneumatic dilatation or surgery were considered repeat responders. Results were compared with those of published studies evaluating the use of botulinum toxin in adults with achalasia. Results: Nineteen patients initially responded to botulinum toxin. Mean duration of effect was 4.2 months ± 4.0 (SD). At the end of the study period, three were repeat responders, three experienced dysphagia but did not receive pneumatic dilatation or surgery, three underwent pneumatic dilatation, eight under- went surgery, three underwent pneumatic dilatation with subsequent surgery, and three awaited surgery. Meta-analysis shows that, in the current study group, the data point expressing time of follow-up evaluation versus percentage of patients needing one injection session without additional procedures (botulinum toxin injection, pneumatic dilatation, or surgery) falls within the curve for those in studies on adult patients receiving botulinum toxin for achalasia. Conclusions: Botulinum toxin effectively initiates the resolution of symptoms associated with achalasia in children. However, one half of patients are expected to need an additional procedure approximately 7 months after one injection session. The authors recommend that botulinum toxin be used only for children with achalasia wh6 are poor candidates for either pneumatic dilatation or surgery. (C) 2000 Lippincott Williams and Wilkins, Inc.

AB - Background: Achalasia is rare in children. Recently, injection of botulinum toxin into the lower esophageal sphincter has been studied as an alternative to esophageal pneumatic dilatation or surgical myotomy as treatment for achalasia. In the current study, the effects of botulinum toxin were investigated in the largest known series of children with achalasia. Methods: Treatment for achalasia was assessed in 23 pediatric patients who received botulinum toxin from June 1995 through November 1998. Those who continued to receive botulinum toxin and did not subsequently undergo pneumatic dilatation or surgery were considered repeat responders. Results were compared with those of published studies evaluating the use of botulinum toxin in adults with achalasia. Results: Nineteen patients initially responded to botulinum toxin. Mean duration of effect was 4.2 months ± 4.0 (SD). At the end of the study period, three were repeat responders, three experienced dysphagia but did not receive pneumatic dilatation or surgery, three underwent pneumatic dilatation, eight under- went surgery, three underwent pneumatic dilatation with subsequent surgery, and three awaited surgery. Meta-analysis shows that, in the current study group, the data point expressing time of follow-up evaluation versus percentage of patients needing one injection session without additional procedures (botulinum toxin injection, pneumatic dilatation, or surgery) falls within the curve for those in studies on adult patients receiving botulinum toxin for achalasia. Conclusions: Botulinum toxin effectively initiates the resolution of symptoms associated with achalasia in children. However, one half of patients are expected to need an additional procedure approximately 7 months after one injection session. The authors recommend that botulinum toxin be used only for children with achalasia wh6 are poor candidates for either pneumatic dilatation or surgery. (C) 2000 Lippincott Williams and Wilkins, Inc.

KW - Achalasia

KW - Botulinum toxin

KW - Esophageal pneumatic dilatation

KW - Heller myotomy

KW - Laparoscopy

KW - Lower esophageal sphincter

UR - http://www.scopus.com/inward/record.url?scp=0034108504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034108504&partnerID=8YFLogxK

U2 - 10.1097/00005176-200005000-00009

DO - 10.1097/00005176-200005000-00009

M3 - Article

C2 - 10817280

AN - SCOPUS:0034108504

VL - 30

SP - 509

EP - 514

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 5

ER -